MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1506)	7/28/2004 1:03:25 PM
From: Icebrg	of 1826

MGI Pharma "outperform" Wednesday, July 28, 2004 8:59:28 AM ET Robert W. Baird NEW YORK, July 28 (New Ratings) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma (MOGN.NAS). The target price is set to $35. In a research note published this morning, the analysts mention that Centers for Medicare & Medicaid Services (CMS) of the US has released its reimbursement schedule for 2005. CMS has included MGI Pharma's product, Aloxi, in the schedule due to the sales growth prospects of the product, the analysts say. The reimbursement rate proposed by CMS is positive for the company, Robert W Baird believes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next